“Do available data support the safety and effectiveness of Moderna Covid-19 vaccine for use under EUA as a booster dose, 50 micrograms mRNA-1273, at least six months after completion of a primary series in the following populations: individuals 65 years of age and older, individuals 18 to 64 years of age at high-risk of severe Covid-19 and individuals 18 through 64 years of age, whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of Covid-19, including severe Covid-19?” “We do have a unanimous 19 out of 19 yes votes, and that concludes the voting portion.”